TY - JOUR T1 - A model to predict SARS-CoV-2 infection based on the first three-month surveillance data in Brazil JF - medRxiv DO - 10.1101/2020.04.05.20047944 SP - 2020.04.05.20047944 AU - Fredi A. Diaz-Quijano AU - José Mário Nunes da Silva AU - Fabiana Ganem AU - Silvano Oliveira AU - Andrea L. Vesga-Varela AU - Julio Croda Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/03/2020.04.05.20047944.abstract N2 - Background COVID-19 diagnosis is a critical problem, mainly due to the lack or delay in the test results. We aimed to obtain a model to predict SARS-CoV-2 infection in suspected patients reported to the Brazilian surveillance system.Methods We analyzed suspected patients reported to the National Surveillance System that corresponded to the following case definition: patients with respiratory symptoms and fever, who traveled to regions with local or community transmission or who had close contact with a suspected or confirmed case. Based on variables routinely collected, we obtained a multiple model using logistic regression. The area under the receiver operating characteristic curve (AUC) and accuracy indicators were used for validation.Results We described 1468 COVID-19 cases (confirmed by RT-PCR) and 4271 patients with other illnesses. With a data subset, including 80% of patients from Sao Paulo (SP) and Rio Janeiro (RJ), we obtained a function which reached an AUC of 95.54% (95% CI: 94.41% - 96.67%) for the diagnosis of COVID-19 and accuracy of 90.1% (sensitivity 87.62% and specificity 92.02%). In a validation dataset including the other 20% of patients from SP and RJ, this model exhibited an AUC of 95.01% (92.51% – 97.5%) and accuracy of 89.47% (sensitivity 87.32% and specificity 91.36%).Conclusion We obtained a model suitable for the clinical diagnosis of COVID-19 based on routinely collected surveillance data. Applications of this tool include early identification for specific treatment and isolation, rational use of laboratory tests, and input for modeling epidemiological trends.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work had no specific funding. FADQ and JC were granted a fellowship for research productivity from the Brazilian National Council for Scientific and Technological Development (CNPq), process/contract identification: 312656/2019-0 and 310551/2018-8, respectively.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData subject to third party restrictions. ER -